VENUSREM

** Shares of Venus Remedies VENR.NS rise 5% to 820.6 rupees, highest in over a month

** Pharma co's Q3 consol net profit rises 30.5% Y/Y, helped by smaller expenses; rev up 2%

** Stock rose 140% in 2025

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Jan 8 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD- RECEIVED MARKETING AUTHORISATION IN INDONESIA FOR ITS ANTIBIOTIC COMBINATION CEFTAZIDIME + AVIBACTAM

Source text: ID:nBSE98GBsr

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 17.21% to 426 rupees, highest since Aug 2024

** Stock last up 11.6%; trading volume at ~15x the 30-day avg, with stock set for most active session since Feb 6

** Pharma firm's March-qtr net profit doubles to 210 mln rupees ($2.5 mln); rev little changed; total costs fall 6%

** Stock now up ~14 YTD

($1 = 85.3500 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Venus Remedies VENR.NS jump 9.2% to 341.50 rupees, set for second-best day this year

** Drugmaker gets U.S. FDA nod to use its anti-microbial resistance therapy, VRP-034

** VRP-034 used for treating injury to kidney caused by polymyxin-based therapies

** Over 197,000 shares traded, 4.2x the 30-day avg volume

** Stock has risen 7.3% so far this year

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

Feb 25 (Reuters) - Venus Remedies Ltd VENR.NS:

• SECURES EXCLUSIVE IN-LICENSING RIGHTS FROM INFEX THERAPEUTICS

• SECURES EXCLUSIVE IN-LICENSING RIGHTS TO DEVELOP, COMMERCIALIZE MET-X IN INDIA

Source text: ID:nBSE7MjRrY

Further company coverage: VENR.NS

(([email protected];;))

** Venus Remedies' stock VENR.NS jump as much as 12.5% to 332.4 rupees; biggest intraday gain since mid-June

** Stock last up ~8% after pharma co renews European Good Manufacturing Practices (GMP) certification for Portugal plant

** Stock on track to log busiest trading session since early-Dec, with volume 3.5x the 30-day avg

** It lost ~22% in 2024 vs 124% gains in 2023

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Jan 20 (Reuters) - Venus Remedies Ltd VENR.NS:

• RENEWS EU GMP CERTIFICATION

Source text: ID:nBSEbnVnH0

Further company coverage: VENR.NS

(([email protected];;))

** Shares of Venus Remedies VENR.NS rise as much as 4.8% to 324.95 rupees

** Pharmaceutical co says it got good manufacturing practice (GMP) certification from Moldova, which will help Eastern European expansion

** Stock on track for a third consecutive session of gain

** More than 35,000 shares change hands, 1.5x of 30-day avg

** Stock down 21.1% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Dec 6 (Reuters) - Venus Remedies Ltd VENR.NS:

• GRANT OF MARKETING AUTHORIZATION FOR PEMETREXED 500 MG IN PHILIPPINES

Source text: ID:nBSEgbZRW

Further company coverage: VENR.NS

(([email protected];;))

** Shares of Venus Remedies VENR.NS rise as much as 2.4% to 314 rupees

** Drug maker on Friday said it will establish a unit in Hungary via its wholly owned subsidiary Venus Pharma GmbH, Germany to enhance market presence in Eastern Europe

** Stock fell 1.5% in Nov., its fourth straight monthly fall

** Stock last up 1.4%, trimming YTD loss to 23.5%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Nov 29 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES - APPROVED SET UP OF HUNGARY UNIT TO EXPAND EASTERN EUROPE MARKET PRESENCE

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS up as much as 5% to 395 rupees, highest since Feb 15

** Drug maker on Wednesday said it won a contract from Pan American Health Organisation for supplying essential cancer drugs to multiple Latin American countries

** Stock pares some gains; last up 2%

** Including day's gains, VENR down ~6% YTD vs 18% surge in pharma index .NIPHARM

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

** Shares of India's Venus Remedies VENR.NS rise as much as 8.7% to 385 rupees, currently up ~6%

** Pharma co receives order from United Nations Children's Fund (UNICEF) for its antibiotic drug, Ceftriaxone 1gm

** Co did not disclose financial details of the order

** Trading vols 6.2x the 30-day avg

** VENR has lost 7.8% so far this year after surging 124% in 2023

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

May 30 (Reuters) - Venus Remedies Ltd VENR.NS:

• MARCH-QUARTER CONSOL NET PROFIT 105.1 MILLION RUPEES VERSUS PROFIT 110.6 MILLION RUPEES

• MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.95 BILLION RUPEES VERSUS 1.56 BILLION RUPEES

Source text for Eikon: ID:nBSE52pZH9

Further company coverage: VENR.NS

(([email protected];))

April 1 (Reuters) - Venus Remedies Ltd VENR.NS:

• AWARDED 25 MILLION RUPEES AS REMAINING PART OF FIRST INCENTIVE UNDER PRODUCTION LINKED INCENTIVE SCHEME

Source text for Eikon: ID:nBSE2q5KJm

Further company coverage: VENR.NS

(([email protected];;))

March 11 (Reuters) - Venus Remedies Ltd VENR.NS:

• SECURED GOOD MANUFACTURING PRACTICES (GMP ) APPROVAL FROM UNICEF

• MANUFACTURING UNIT IN BADDI APPROVED TO SUPPLY UNICEF WITH CEPHALOSPORIN ANTIBIOTICS

Source text for Eikon: ID:nBSE5jR9WN

Further company coverage: VENR.NS

(([email protected];))

March 8 (Reuters) - Venus Remedies Ltd VENR.NS:

• RECEIVES MARKETING AUTHORIZATIONS FOR ONCOLOGY DRUGS IN UKRAINE

Source text for Eikon: ID:nBSE1ZJB1N

Further company coverage: VENR.NS

(([email protected];))

March 6 (Reuters) - Venus Remedies Ltd VENR.NS:

• AWARDED ITS FIRST DISBURSEMENT OF 75 MILLION RUPEES UNDER PRODUCTION LINKED INCENTIVE SCHEME

Further company coverage: VENR.NS

(([email protected];))

Feb 14 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD DEC-QUARTER CONSOL NET PROFIT 68.5 MILLION RUPEES VERSUS 32.9 MILLION RUPEES

• VENUS REMEDIES LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.43 BILLION RUPEES VERSUS 1.17 BILLION RUPEES

Source text for Eikon: ID:nBSE3vZ8DB

Further company coverage: VENR.NS

(([email protected];))

Jan 18 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LIMITED ATTAINS GMP CERTIFICATION FROM LIBYA

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS rise as much as 4.18% to 425 rupees; stock last up 3.2%

** Pharma company receives new marketing authorizations for two drugs in Malta, Europe

** Approvals to help in expanding global reach, says VENR

** Trading volume is 123,997 shares as of 12:05 p.m. IST, 1.1x the 30-day avg - LSEG data

** VENR shares up 4.4% in January so far, after jumping 124.32% in 2023

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Dec 21 (Reuters) - Venus Remedies Ltd VENR.NS:

• ACHIEVES MARKETING AUTHORIZATIONS FOR DOCETAXEL IN ISRAEL AND CYTARABINE IN COLOMBIA

Source text for Eikon: ID:nBSE1gSKBR

Further company coverage: VENR.NS

(([email protected];;))

Dec 20 (Reuters) - Venus Remedies Ltd VENR.NS:

• FORAYS INTO WELLNESS ARENA

Further company coverage: VENR.NS

(([email protected];))

Dec 18 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES LTD - SUCCESSFULLY OBTAINED THREE NEW MARKETING AUTHORIZATIONS FOR ENOXAPARIN FROM BAHRAIN

Source text for Eikon: ID:nBSE6jNMDN

Further company coverage: VENR.NS

(([email protected];;))

Dec 5 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES GRANTED MARKET AUTHORIZATION FOR ENOXAPARIN IN AZERBAIJAN

Source text for Eikon: ID:nBSEQjGk2

Further company coverage: VENR.NS

(([email protected];))

Dec 1 (Reuters) - Venus Remedies Ltd VENR.NS:

• GRANTED MARKET AUTHORIZATIONS IN SAUDI ARABIA AND PHILIPPINES

• GRANTED MARKET AUTHORIZATIONS IN SAUDI ARABIA AND PHILIPPINES

• MARKETING AUTHORIZATIONS FOR PACLITAXEL AND ZOLENDRONIC ACID 4MG

• MARKETING AUTHORIZATIONS FOR PACLITAXEL AND ZOLENDRONIC ACID 4MG IN PHILIPPINES

• GETS MARKET AUTHORIZATION FOR BLEOMYCIN FROM SAUDIA RABIA

Source text for Eikon: ID:nBSE6N92Kb

Further company coverage: VENR.NS

(([email protected];;))

Nov 9 (Reuters) - Venus Remedies Ltd VENR.NS:

• INDIA'S VENUS REMEDIES LTD SEPT-QUARTER CONSOL NET PROFIT 99.4 MILLION RUPEES VERSUS PROFIT 53.3 MILLION RUPEES

• VENUS REMEDIES LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.68 BILLION RUPEES VERSUS 1.40 BILLION RUPEES

Source text for Eikon: ID:nNSE1SXtMd

Further company coverage: VENR.NS

(([email protected];))

Nov 6 (Reuters) - Venus Remedies Ltd VENR.NS:

• SECURES 'THREE STAR EXPORT HOUSE" CERTIFICATE FROM GOVERNMENT OF INDIA

Source text for Eikon: ID:nNSE9pjsbX

Further company coverage: VENR.NS

(([email protected];))

** Shares of Venus Remedies VENR.NS surge as much as 9.29% to 258.15 rupees per share, before erasing gains amid selling pressure in markets

** Pharmaceutical company's unit receives market authorisation in the United Kingdom for Bleomycin, a drug used in chemotherapy to treat cancer

** VENR now has a total of 15 market authorisations globally for the chemotherapy drug

** Trading volume is 103,645 shares as of 10:46 a.m. IST, twice the 30-day avg - LSEG data

** Including day's gains, VENR shares up 31.3% in 2023 so far

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

Oct 16 (Reuters) - Venus Remedies Ltd VENR.NS:

• VENUS REMEDIES CONSOLIDATES IN ASEAN, GETS MARKETING APPROVAL FOR SIX CHEMOTHERAPY DRUGS FROM PHILIPPINES

• VENUS REMEDIES' ONCOLOGY WING HAS ALSO SECURED MARKETING AUTHORISATION FROM MYANMAR FOR ANOTHER CHEMOTHERAPY DRUG

Source text for Eikon: ID:nBSE20P725

Further company coverage: VENR.NS

(([email protected];))